Omada Health (OMDA) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
8 May, 2026Executive summary
Revenue grew 42% year-over-year to $78 million in Q1 2026, with total members surpassing 1.02 million, up 51% year-over-year, driven by new customer acquisition and program expansion.
Expanded partnerships now include all three major PBMs, covering up to 80% of prescription claims in 2025, and direct-to-employer offerings, including collaborations with Optum Rx and Eli Lilly.
Demonstrated clinical leadership with 30 peer-reviewed studies and new analysis showing GLP-1 Care Track members lost 1.8x more weight and over 2x more body fat than controls in 12 weeks.
AI-driven operational efficiencies and enhanced member engagement contributed to improved margins and scalability.
Announced role as independent program administrator for Eli Lilly's Employer Connect program, expanding GLP-1 access.
Financial highlights
Q1 2026 revenue was $78 million, up from $54.96 million in Q1 2025 (42% growth); gross profit reached $48.7 million, and gross margin improved to 62% GAAP and 64% non-GAAP.
Net loss narrowed to $3 million from $9 million year-over-year; adjusted EBITDA reached $1 million, a $5 million improvement year-over-year.
Cash and cash equivalents stood at $212 million at quarter end, with no debt outstanding.
Free cash flow was negative $13.4 million, an improvement from negative $17.4 million in Q1 2025.
Non-GAAP operating expenses increased 28% to $182 million, but as a percentage of revenue, fell from 75% to 64%.
Outlook and guidance
Raised full-year 2026 revenue guidance to $322–$330 million, representing ~25% year-over-year growth, and increased adjusted EBITDA guidance to $14–$20 million, nearly tripling 2025 levels.
New and expanded commercial relationships and GLP-1 Care Track expected to drive durable growth and margin expansion, with major revenue contributions from new programs anticipated in 2027.
Management expects continued growth through customer acquisition, program expansion, and increased member enrollment.
Current liquidity is expected to fund operations for at least the next 12 months; future capital needs will depend on growth rate and investment opportunities.
Positioned for continued growth with scalable business model and expanding addressable market.
Latest events from Omada Health
- 53% revenue growth, margin expansion, and new programs set up strong 2026 outlook.OMDA
Q4 202530 Apr 2026 - Shareholders will vote on director elections and auditor ratification, with strong governance and oversight.OMDA
Proxy filing28 Apr 2026 - Vote to elect two directors and ratify Deloitte & Touche LLP as auditor at the June 2026 meeting.OMDA
Proxy filing28 Apr 2026 - 52% revenue growth, 886,000 members, and new GLP-1 prescribing drive Omada's momentum.OMDA
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - GLP-1 prescribing and AI-driven care are driving growth, efficiency, and expanded market opportunities.OMDA
Evercore ISI 8th Annual HealthCONx Conference13 Dec 2025 - IPO seeks $133M+ to fund growth; strong revenue, large market, but not yet profitable.OMDA
Registration Filing29 Nov 2025 - 38% revenue growth in 2024, strong retention, but still unprofitable; IPO to fund expansion.OMDA
Registration Filing29 Nov 2025 - Q2 2025 revenue rose 49% to $61.4M, margin expanded, and net loss narrowed to $5.3M.OMDA
Q2 202523 Nov 2025 - Q3 2025 delivered record revenue and member growth, positive adjusted EBITDA, and raised guidance.OMDA
Q3 202513 Nov 2025